Anika Therapeutics (ANIK) Amortization of Deferred Charges (2021 - 2026)
Anika Therapeutics (ANIK) posted quarterly Amortization of Deferred Charges of $465000.0 for Q2 2026, down 5.1% year-over-year from $490000.0 in Q2 2025, and little changed quarter-over-quarter from $464000.0 in Q1 2026.
Anika Therapeutics (ANIK) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Amortization of Deferred Charges for 6 consecutive years, with $465000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortization of Deferred Charges fell 5.1% year-over-year to $465000.0; the TTM figure through Jun 2026 stood at $1.9 million (down 14.23% YoY), while the FY2025 annual figure was $2.1 million, down 4.14% from the prior year.
- Amortization of Deferred Charges was little changed at $465000.0 in Q2 2026 per ANIK's latest filing, from $464000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $598000.0 in Q4 2023 and bottomed at $394000.0 in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $512277.8 across 5 years, with a median of $526500.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges jumped 38.07% — and 2024, when it dropped 24.63%.
- Anika Therapeutics' Amortization of Deferred Charges stood at $528000.0 in 2022, then advanced by 13.26% to $598000.0 in 2023, then retreated by 1.51% to $589000.0 in 2024, then dropped by 15.28% to $499000.0 in 2025, then decreased by 6.81% to $465000.0 in 2026.
- Business Quant data shows ANIK's Amortization of Deferred Charges at $465000.0 in Q2 2026, $464000.0 in Q1 2026, and $499000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 465,000.00 |
| Jun 30, 2026 | 465,000.00 |
| Mar 31, 2026 | 464,000.00 |
| Mar 31, 2026 | 464,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Sep 30, 2025 | 495,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 577,000.00 |
| Mar 31, 2025 | 577,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 586,000.00 |
| Sep 30, 2024 | 586,000.00 |
| Jun 30, 2024 | 410,000.00 |
| Jun 30, 2024 | 410,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Mar 31, 2024 | 565,000.00 |